Growth-Differentiation Factor 15 and Osteoprotegerin in Acute Myocardial Infarction Complicated by Cardiogenic Shock: A Biomarker Substudy of the IABP-SHOCK II-Trial
Authors:
Open Access
- 5 June 2014
- journal article
- research article
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 16 (8) , 880-887
Abstract
Aims This study investigates the role of osteoprotegerin (OPG) and growth‐differentiation factor 15 (GDF‐15) as predictors of outcome in cardiogenic shock (CS) complicating acute myocardial infarction. The novel biomarkers OPG and GDF‐15 have shown prognostic impact in various cardiovascular diseases including myocardial infarction. In acute myocardial infarction complicated by CS, the diagnostic and prognostic impact of these biomarkers has not been investigated yet. OPG and GDF‐15 may have additional prognostic impact on early prognosis assessment, being potentially useful for decision‐making in CS. Methods and results In the randomized Intra‐aortic Balloon Pump in cardiogenic Shock II (IABP‐SHOCK II)‐trial, 600 patients with CS complicating acute myocardial infarction undergoing early revascularization were assigned to therapy with or without IABP. Within a pre‐defined substudy, blood samples were collected from 190 patients during PCI. GDF‐15 and OPG serum levels were measured with standard enzyme‐linked immunosorbent assay kits. Patients with GDF‐15 and OPG levels greater than the median showed higher rates of death at 30 days by χ2 testing (OPG, 51% vs. 32%, P = 0.01; GDF‐15, 52% vs. 31%, P = 0.005) and log rank testing [GDF‐15, hazard ratio (HR) 1.88, 95% confidence interval (CI) 1.21–2.94; P = 0.005; OPG, HR 1.74, 95% CI 1.11–2.71; P = 0.01]. Both markers were significantly predictive of 30‐day mortality in univariable logistic regression analysis. In a multivariable logistic stepwise regression model, GDF‐15, TIMI (Thrombolysis In Myocardial Infarction) flow grade <3 after PCI, age, LVEF, and serum lactate remained significant predictors of 30‐day mortality. Conclusion GDF‐15 on admission is a significant independent predictor of short‐term mortality in infarct‐related CS. Trail registration: NCT00491036Keywords
Funding Information
- Deutsche Forschungsgemeinschaft
- German Cardiac Society
- German Heart Research Foundation
- Arbeitsgemeinschaft Leitende Kardiologische Krankenhaus�rzte
This publication has 29 references indexed in Scilit:
- Osteoprotegerin in ST-elevation myocardial infarction: Prognostic impact and association with markers of myocardial damage by magnetic resonance imagingInternational Journal of Cardiology, 2013
- Relation of Circulating Osteoprotegerin Levels on Admission to Microvascular Obstruction After Primary Percutaneous Coronary InterventionThe American Journal of Cardiology, 2011
- Growth-differentiation factor 15 as predictor of mortality in acute reperfused ST-elevation myocardial infarction: insights from cardiovascular magnetic resonanceHeart, 2011
- The Percutaneous Ventricular Assist Device in Severe Refractory Cardiogenic ShockJACC, 2011
- Percutaneous left ventricular assist devices vs. intra-aortic balloon pump counterpulsation for treatment of cardiogenic shock: a meta-analysis of controlled trialsEuropean Heart Journal, 2009
- Thirty-Year Trends (1975 to 2005) in the Magnitude of, Management of, and Hospital Death Rates Associated With Cardiogenic Shock in Patients With Acute Myocardial InfarctionCirculation, 2009
- Increased plasma osteoprotegerin levels are associated with the presence and severity of acute coronary syndromeActa Cardiologica, 2008
- Circulating Osteoprotegerin Levels and Long-Term Prognosis in Patients With Acute Coronary SyndromesJACC, 2008
- Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarctionEuropean Heart Journal, 2007
- Prognostic Value of Growth-Differentiation Factor-15 in Patients With Non–ST-Elevation Acute Coronary SyndromeCirculation, 2007